Larry Kilgore, MD
Gynecologic Oncology · Knoxville, TNNPI 1265482921
Payments from drug & device makers
What this record shows
The money is spread across several categories — consulting fees (51.6%), food and beverage and education — rather than concentrated in one kind of arrangement. 22 manufacturers reported payments, led by AstraZeneca at 56.1% of the total. Reporting peaked in 2019 at $3,947 and has fallen 82.4% since, to $695 in 2025.
Across 139 payments — averaging $48.14 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$4K
- Merck$817
- GSK$338
- AbbVie$314
- Intuitive Surgical$289
- Eisai Inc.$214
- plus $963 from 16 others
Across 52 payments — averaging $4695.47 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- GSK$168K
- AstraZeneca$39K
- Karyopharm Therapeutics Inc.$33K
- Eli Lilly$3K
- Eisai Inc.$2K
What the payments were for
- Consulting fees$3,45052%
- Food & beverage$3,08146%
- Education$1602%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 15 | $3,756 |
| Merck | 40 | $817 |
| GSK | 13 | $338 |
| AbbVie | 14 | $314 |
| Intuitive Surgical | 4 | $289 |
| Eisai Inc. | 10 | $214 |
| Clovis Oncology, Inc. | 8 | $134 |
| Immunogen, Inc. | 5 | $113 |
| Johnson & Johnson | 4 | $106 |
| Daiichi Sankyo Inc. | 4 | $102 |
| Seagen Inc. | 5 | $93 |
| Tempus AI, Inc | 3 | $83 |
| Tactile Systems Technology Inc | 2 | $73 |
| Caris MPI, Inc. | 2 | $49 |
| Conmed Corporation | 2 | $40 |
| Tesaro, Inc. | 2 | $32 |
| Astellas Pharma US Inc | 1 | $30 |
| Baxter Healthcare | 1 | $25 |
| Biom'up France SAS | 1 | $23 |
| Pfizer | 1 | $22 |
| KCI USA, Inc. | 1 | $20 |
| Foundation Medicine, Inc. | 1 | $17 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- LYNPARZA$3,450
- Da Vinci Surgical System$140
- ZEJULA$111
How this compares
$6,691 in reported general payments places this provider in the 70th percentile of 40 gynecologic oncology providers in Tennessee.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Medroxyprogesterone Acetate | 14 | $312 |
| Ondansetron Hcl | 11 | $71 |
Paid to pharmacies, not to this prescriber.
Other gynecologic oncology in Knoxville
- Jonathan BooneKnoxville$4K
- Kristopher KimballKnoxville$4K
- David MartinKnoxville$1K
- Brook SaundersKnoxville$892
- Kenneth CoferKnoxville$390
- Don HallKnoxville$30
- Todd TillmannsGermantown$127K
- Ronald AlvarezNashville$33K
- Adam ElnaggarGermantown$29K
- Michael StanyNashville$13K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.